

# Alberto Floris

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6775962/publications.pdf>

Version: 2024-02-01

40  
papers

775  
citations

706676

14  
h-index

591227

27  
g-index

41  
all docs

41  
docs citations

41  
times ranked

1169  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. <i>Clinical Rheumatology</i> , 2022, 41, 19-31.	1.0	28
2	Telemedicine in rheumatology: high specificity and sensitivity of follow-up virtual video consultations during COVID-19 pandemic. <i>Rheumatology</i> , 2022, 61, 1795-1801.	0.9	22
3	Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group. <i>European Journal of Internal Medicine</i> , 2022, 96, 60-65.	1.0	12
4	Musculoskeletal ultrasound may narrow the gap between patients and physicians in the assessment of rheumatoid arthritis disease activity. <i>Rheumatology</i> , 2022, 62, 116-123.	0.9	1
5	Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review. <i>BioDrugs</i> , 2021, 35, 175-186.	2.2	2
6	Gene Expression Profiling of Monozygotic Twins Affected by Psoriatic Arthritis. <i>Open Access Rheumatology: Research and Reviews</i> , 2021, Volume 13, 23-29.	0.8	2
7	Current smoking predicts inadequate response to methotrexate monotherapy in rheumatoid arthritis patients naïve to DMARDs. <i>Medicine (United States)</i> , 2021, 100, e25481.	0.4	7
8	Targeted Therapies in Axial Psoriatic Arthritis. <i>Frontiers in Genetics</i> , 2021, 12, 689984.	1.1	1
9	Imbalanced MMP-3 and MMP-12 serum levels in systemic lupus erythematosus patients with Jaccoud's arthropathy and a distinctive MRI pattern. <i>Rheumatology</i> , 2021, 60, 4218-4228.	0.9	5
10	Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage. <i>Arthritis Care and Research</i> , 2020, 72, 1794-1799.	1.5	13
11	Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort. <i>Rheumatology</i> , 2020, 59, 2272-2281.	0.9	25
12	Discordance between patient and physician global assessment of disease activity in Behçet's syndrome: a multicenter study cohort. <i>Arthritis Research and Therapy</i> , 2020, 22, 278.	1.6	7
13	Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties. <i>Rheumatology</i> , 2020, 59, 3622-3632.	0.9	39
14	Assessment Of Circulating Endothelial Cells And Their Progenitors As Potential Biomarkers Of Disease Activity And Damage Accrual In Behçet's Syndrome. <i>Open Access Rheumatology: Research and Reviews</i> , 2019, Volume 11, 219-227.	0.8	2
15	THU0299...PATIENT GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN BEHÇET'S SYNDROME: A MULTICENTER STUDY. , 2019, , .		0
16	SAT0035...IS PHARMACOLOGICAL CLINICAL REMISSION SYNONYMOUS WITH BIOLOGICAL INACTIVE DISEASE? DIFFERENTIAL GENE EXPRESSION ANALYSIS IN RHEUMATOID ARTHRITIS AND HEALTHY CONTROLS. , 2019, , .		0
17	SAT0240...DEVELOPMENT AND PRELIMINARY VALIDATION OF THE BEHÇET'S SYNDROME OVERALL DAMAGE INDEX (BODI). , 2019, , .		0
18	FRI0357...DRUG-INDUCED REMISSION AND SUBCLINICAL ACTIVITY IN PSORIATIC ARTHRITIS: TRANSCRIPTIONAL PROFILING TO CHARACTERIZE THE DISEASE STATE. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
19	THU0095â€¦CIGARETTE SMOKING AS PREDICTOR OF INADEQUATE RESPONSE TO METHOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS NAËVE TO DMARDS. , 2019, , .		0
20	The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist. <i>Rheumatology</i> , 2018, 57, 227-235.	0.9	101
21	Musculoskeletal manifestations as determinants of quality of life impairment in patients with systemic lupus erythematosus. <i>Lupus</i> , 2018, 27, 190-198.	0.8	39
22	The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice. <i>Rheumatology</i> , 2018, 57, 112-119.	0.9	53
23	ALF-1 gene does not confer susceptibility to Behçetâ€™s disease: Analysis of extended haplotypes in Sardinian population. <i>PLoS ONE</i> , 2018, 13, e0204250.	1.1	4
24	Polymyalgia rheumatica: an autoinflammatory disorder?. <i>RMD Open</i> , 2018, 4, e000694.	1.8	15
25	Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. <i>Mediators of Inflammation</i> , 2018, 2018, 1-11.	1.4	56
26	Expression analysis of HLA-E and NKG2A and NKG2C receptors points at a role for natural killer function in ankylosing spondylitis. <i>RMD Open</i> , 2018, 4, e000597.	1.8	9
27	Physicianâ€™s Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. <i>Journal of Rheumatology</i> , 2018, 45, 1256-1262.	1.0	10
28	Demyelinating syndrome in SLE encompasses different subtypes: Do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. <i>Autoimmunity Reviews</i> , 2017, 16, 244-252.	2.5	41
29	Comment on: Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease. <i>Rheumatology</i> , 2017, 56, 2038-2039.	0.9	2
30	Demyelinating syndrome in SLE: review of different disease subtypes and report of a case series. <i>Reumatismo</i> , 2017, 69, 175-183.	0.4	12
31	Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab: an alternative to standard of care. <i>Open Access Rheumatology: Research and Reviews</i> , 2017, Volume 9, 167-170.	0.8	4
32	Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2017, 19, 247.	1.6	66
33	Predictors of flares in Systemic Lupus Erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. <i>Autoimmunity Reviews</i> , 2016, 15, 656-663.	2.5	51
34	Population-based analysis of hospitalizations for patients with systemic sclerosis in a West-European region over the period 2001â€“2012. <i>Rheumatology International</i> , 2016, 36, 73-81.	1.5	12
35	Population-based analysis of hospitalizations in a West-European region revealed major changes in hospital utilization for patients with systemic lupus erythematosus over the period 2001â€“2012. <i>Lupus</i> , 2016, 25, 28-37.	0.8	28
36	Current perspective on the role of the interleukin-23/interleukin-17 axis in inflammation and disease (chronic arthritis and psoriasis). <i>ImmunoTargets and Therapy</i> , 2015, 4, 185.	2.7	9

#	ARTICLE	IF	CITATIONS
37	New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol. <i>Journal of rheumatology Supplement, The</i> , 2015, 93, 70-72.	2.2	10
38	Killerâ€Cell Immunoglobulinâ€Like Receptors (<scp>KIR</scp>) and <scp>HLA</scp>â€Class <scp>I</scp> Heavy Chains in Ankylosing Spondylitis. <i>Drug Development Research</i> , 2014, 75, S15-9.	1.4	11
39	Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: Systematic literature review and analysis of a monocentric cohort. <i>Autoimmunity Reviews</i> , 2014, 13, 873-879.	2.5	71
40	277â€fUsing the Birmingham Vasculitis Activity Score as a Screening Tool in Patients with Suspected Vasculitis. <i>Rheumatology</i> , 0, , .	0.9	0